Key statistics
On Monday, Supernus Pharmaceuticals Inc (0LB2:LSE) closed at 52.00, -9.72% below its 52-week high of 57.60, set on Oct 30, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 52.00 |
| Low | 52.00 |
| Bid | -- |
| Offer | -- |
| Previous close | 51.01 |
| Average volume | 29.50 |
|---|---|
| Shares outstanding | 57.34m |
| Free float | 54.89m |
| P/E (TTM) | -- |
| Market cap | 2.96bn USD |
| EPS (TTM) | -0.3408 USD |
Data delayed at least 20 minutes, as of Feb 09 2026 14:39 GMT.
More ▼
- Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
- Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
- Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
- Supernus Announces Third Quarter 2025 Financial Results
- Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
- Supernus Pharmaceuticals to Participate in September Investor Conferences
- Supernus Announces Second Quarter 2025 Financial Results
- Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
- Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
- Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
More ▼
